세계의 파브리병 시장 보고서(2025년)

Fabry Disease Global Market Report 2025

US $ 4,490 ￦ 6,217,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,987,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,756,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

파브리병 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 8.0%의 연평균 성장률(CAGR)로 31억 달러에 달할 것으로 예상됩니다. 예측 기간 동안 성장의 원동력은 신생아 선별검사 프로그램 확대, 희귀질환 치료에 대한 규제 당국의 지원, 보다 광범위한 의료 접근성, 원격의료 및 원격진료의 부상, 맞춤형 의료에 대한 수요 증가에 기인할 것으로 보입니다. 이 기간의 주요 동향으로는 효소 대체 요법의 채택, 유전자 검사의 발전, 조기 발견을 위한 AI와 디지털 도구의 통합, AI를 활용한 진단 알고리즘, 유전자 치료의 발전 등을 꼽을 수 있습니다.

개인맞춤의료의 중요성이 부각되면서 향후 패브리병 시장의 성장이 예상됩니다. 맞춤형 의료는 개인의 유전적 체질, 환경, 라이프스타일에 따라 치료를 조정하여 치료 결과를 향상시킵니다. 이 접근법은 특정 환자의 필요에 따라 치료를 맞춤화하여 치료 효과를 높이고 부작용을 줄임으로써 치료 효과를 높입니다. 맞춤의료는 환자별 유전자 변이 및 질병 중증도를 고려한 치료 계획을 개발할 수 있어 치료 결과를 개선하고 부작용을 감소시킬 수 있습니다. 예를 들어, 2024년 2월 미국 비영리단체인 개인맞춤의료연합(Personalized Medicine Coalition)은 FDA가 2023년 희귀질환 환자를 위해 새로 승인한 개인맞춤치료제는 16건으로 2022년 6건보다 크게 증가했다고 지적했습니다. 이에 따라 맞춤형 의료에 대한 관심이 높아진 것이 파브리병 시장 확대를 촉진하는 중요한 요인이 되고 있습니다.

파브리병 시장의 주요 기업들은 PEG화 효소대체요법(ERT)과 같은 혁신적인 치료법에 집중하여 치료 결과를 개선하고, 환자의 순응도를 높이며, 기존 ERT와 관련된 면역계 반응을 완화하기 위해 노력하고 있습니다. 폴리에틸렌 글리콜(PEG)을 첨가하여 안정성을 향상시켜 체내 투여 기간을 연장하고 면역반응을 최소화합니다. 예를 들어, 2023년 5월 Chiesi 그룹에 속한 Chiesi Global Rare Diseases는 미국 식품의약국(FDA)이 PRX-102(pegunigalsidase alfa)를 성인 파브리병 환자의 치료제로 승인했다고 발표했습니다. 이번 승인은 140명 이상의 환자를 대상으로 한 종합적인 임상 프로그램과 최대 7.5년의 장기 추적관찰을 통해 본 치료제가 우수한 안전성 프로파일과 함께 신장의 Gb3 침착물 감소 및 신장 기능 유지에 효과적임을 입증한 데 따른 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 파브리병 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 파브리병 시장 : 성장률 분석
• 세계의 파브리병 시장 실적 : 규모와 성장, 2019-2024년
• 세계의 파브리병 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계의 파브리병 전체 시장(TAM)

제6장 시장 세분화

• 세계의 파브리병 시장 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 유형 1
• 유형 2
• 기타 유형
• 세계의 파브리병 시장 : 치료별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 효소보충요법
• 구강 요법
• 보조 요법
• 기타 치료법
• 세계의 파브리병 시장 : 진단별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 혈액 검사
• 유전자 검사
• 비경구 검사
• 기타 진단
• 세계의 파브리병 시장 : 유통 채널별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원 약국
• 온라인 약국
• 소매 약국
• 세계의 파브리병 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원
• 홈케어
• 전문 클리닉
• 기타 최종사용자
• 세계의 파브리병 시장, 유형 1하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 클래식 파브리병
• 후발성 파브리병
• 세계의 파브리병 시장, 유형 2하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 심혈관 계에 초점을 맞춘 파브리병
• 신장에 초점을 맞춘 파브리병
• 세계의 파브리병 시장, 기타 유형 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 변이체 파브리병
• X링크된 파브리병

제7장 지역별·국가별 분석

• 세계의 파브리병 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 파브리병 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 파브리병 시장 : 경쟁 구도
• 파브리병 시장 : 기업 개요
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • JCR Pharmaceuticals Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Sumitomo Pharma Co. Ltd Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업과 혁신적 기업

• Chiesi Farmaceutici S.p.A.
• Amicus Therapeutics Inc.
• Idorsia Pharmaceuticals Ltd
• Sangamo Therapeutics Inc.
• uniQure N.V.
• Protalix BioTherapeutics Inc.
• Spur Therapeutics Inc.
• Exegenesis Bio Inc.
• ISU ABXIS Co. Ltd.
• Eleva GmbH
• AceLink Therapeutics Inc.
• 4D Molecular Therapeutics Inc.
• iBio Inc.
• Freeline Therapeutics Holdings plc
• Greenovation Biotech GmbH

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 파브리병 시장 2029년 : 새로운 기회를 제공하는 국가
• 파브리병 시장 2029년 : 새로운 기회를 제공하는 부문
• 파브리병 시장 2029년 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

Fabry disease is an uncommon genetic condition resulting from a shortage of the enzyme alpha-galactosidase A, which causes fat to accumulate in the cells and organs of the body. Treatment aims to alleviate symptoms, prevent further organ damage, and enhance the quality of life for those affected.

Fabry disease has several forms, including types 1, 2, and others. Type 1 Fabry disease, a rare genetic disorder that typically starts in childhood, is caused by a near-total absence of the alpha-galactosidase A enzyme, leading to the accumulation of fat in cells and organs. Treatment options include enzyme replacement therapy, oral medications, adjunct therapies, and additional methods. Diagnosis is achieved through various techniques, including blood tests, genetic testing, parenteral tests, and other diagnostic approaches. Distribution channels for treatment include hospital pharmacies, online pharmacies, and retail pharmacies, serving different end users such as hospitals, homecare providers, specialty clinics, and other healthcare facilities.

The fabry disease market research report is one of a series of new reports from The Business Research Company that provides fabry disease market statistics, including the fabry disease industry global market size, regional shares, competitors with the fabry disease market share, detailed fabry disease market segments, market trends, and opportunities, and any further data you may need to thrive in the fabry disease industry. This fabry disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fabry disease market size has grown strongly in recent years. It will grow from $2.10 billion in 2024 to $2.28 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth observed in the historical period can be credited to factors such as heightened awareness and diagnosis of rare diseases, the development of specialized healthcare infrastructure, government incentives and orphan drug designations, increased funding for rare disease research, and the initial introduction of therapies.

The fabry disease market size is expected to see strong growth in the next few years. It will grow to $3.10 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period is expected to be driven by the expansion of newborn screening programs, regulatory support for orphan and rare disease treatments, broader healthcare access, the rise of telemedicine and remote care, and a growing demand for personalized medicine. Key trends during this period include the adoption of enzyme replacement therapy, advancements in genetic testing, the integration of AI and digital tools for early detection, AI-powered diagnostic algorithms, and progress in gene therapy.

The increasing emphasis on personalized medicine is anticipated to drive the growth of the Fabry disease market in the future. Personalized medicine tailors treatments based on an individual's genetic makeup, environment, and lifestyle, which improves treatment outcomes. This approach enhances treatment effectiveness and reduces side effects by customizing therapies to meet specific patient needs. Personalized medicine enables the development of treatment plans that consider a patient's unique genetic mutation and disease severity, resulting in better outcomes and fewer adverse effects. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit, noted that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a significant rise from six approvals in 2022. As a result, the growing emphasis on personalized medicine is a key factor driving the expansion of the Fabry disease market.

Major companies in the Fabry disease market are focusing on innovative therapies, such as PEGylated enzyme replacement therapy (ERT), to improve treatment outcomes, enhance patient adherence, and reduce immune system reactions linked to traditional ERT. PEGylated ERT is a modified version of standard ERT, where polyethylene glycol (PEG) is added to the enzyme to improve stability, extend its duration in the body, and minimize immune responses. For example, in May 2023, Chiesi Global Rare Diseases, part of the Chiesi Group, announced that the U.S. Food and Drug Administration (FDA) approved PRX-102 (pegunigalsidase alfa) for the treatment of adult Fabry disease patients. The approval was supported by a comprehensive clinical program involving over 140 patients and long-term follow-up of up to 7.5 years, demonstrating the therapy's effectiveness in reducing kidney Gb3 deposits and maintaining kidney function, with a favorable safety profile.

In June 2022, Kyorin, a Japan-based pharmaceutical company, acquired a license from CellGenTech to develop and commercialize a treatment for Fabry disease. With this acquisition, Kyorin intends to leverage CellGenTech's genetically modified human adipocytes (GMAC) technology to create a new treatment for Fabry disease. CellGenTech Inc. is a biotechnology company from Japan that specializes in ex vivo gene therapy solutions for rare diseases, including Fabry disease.

Major players in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH.

North America was the largest region in the fabry disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fabry disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fabry disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fabry disease market consists of revenues earned by entities by providing services such as genetic counseling, patient support programs, clinical trials and research services, and disease monitoring and management services. The market value includes the value of related goods sold by the service provider or contained within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fabry Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fabry disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fabry disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fabry disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Type 1; Type 2; Other Types
• 2) By Treatment: Enzyme Replacement Therapy; Oral Therapy; Adjunct Therapy; Other Treatments
• 3) By Diagnosis: Blood Test; Genetic Test; Parenteral Test; Other Diagnosis
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegment:
• 1) By Type 1: Classic Fabry Disease; Later-Onset Fabry Disease
• 2) By Type 2: Cardiovascular-Focused Fabry Disease; Renal-Focused Fabry Disease
• 3) By Other Types: Variant Fabry Disease; X-linked Fabry Disease
• Companies Mentioned: Sanofi S.A.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; JCR Pharmaceuticals Co. Ltd.; Sumitomo Pharma Co. Ltd
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Fabry Disease Market Characteristics

3. Fabry Disease Market Trends And Strategies

4. Fabry Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Fabry Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Fabry Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Fabry Disease Market Growth Rate Analysis
• 5.4. Global Fabry Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Fabry Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Fabry Disease Total Addressable Market (TAM)

6. Fabry Disease Market Segmentation

• 6.1. Global Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1
• Type 2
• Other Types
• 6.2. Global Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme Replacement Therapy
• Oral Therapy
• Adjunct Therapy
• Other Treatments
• 6.3. Global Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Test
• Genetic Test
• Parenteral Test
• Other Diagnosis
• 6.4. Global Fabry Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Fabry Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Fabry Disease Market, Sub-Segmentation Of Type 1, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classic Fabry Disease
• Later-Onset Fabry Disease
• 6.7. Global Fabry Disease Market, Sub-Segmentation Of Type 2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiovascular-Focused Fabry Disease
• Renal-Focused Fabry Disease
• 6.8. Global Fabry Disease Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Variant Fabry Disease
• X-linked Fabry Disease

7. Fabry Disease Market Regional And Country Analysis

• 7.1. Global Fabry Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Fabry Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Fabry Disease Market

• 8.1. Asia-Pacific Fabry Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Fabry Disease Market

• 9.1. China Fabry Disease Market Overview
• 9.2. China Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Fabry Disease Market

• 10.1. India Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Fabry Disease Market

• 11.1. Japan Fabry Disease Market Overview
• 11.2. Japan Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Fabry Disease Market

• 12.1. Australia Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Fabry Disease Market

• 13.1. Indonesia Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Fabry Disease Market

• 14.1. South Korea Fabry Disease Market Overview
• 14.2. South Korea Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Fabry Disease Market

• 15.1. Western Europe Fabry Disease Market Overview
• 15.2. Western Europe Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Fabry Disease Market

• 16.1. UK Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Fabry Disease Market

• 17.1. Germany Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Fabry Disease Market

• 18.1. France Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Fabry Disease Market

• 19.1. Italy Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Fabry Disease Market

• 20.1. Spain Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Fabry Disease Market

• 21.1. Eastern Europe Fabry Disease Market Overview
• 21.2. Eastern Europe Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Fabry Disease Market

• 22.1. Russia Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Fabry Disease Market

• 23.1. North America Fabry Disease Market Overview
• 23.2. North America Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Fabry Disease Market

• 24.1. USA Fabry Disease Market Overview
• 24.2. USA Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Fabry Disease Market

• 25.1. Canada Fabry Disease Market Overview
• 25.2. Canada Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Fabry Disease Market

• 26.1. South America Fabry Disease Market Overview
• 26.2. South America Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Fabry Disease Market

• 27.1. Brazil Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Fabry Disease Market

• 28.1. Middle East Fabry Disease Market Overview
• 28.2. Middle East Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Fabry Disease Market

• 29.1. Africa Fabry Disease Market Overview
• 29.2. Africa Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Fabry Disease Market Competitive Landscape And Company Profiles

• 30.1. Fabry Disease Market Competitive Landscape
• 30.2. Fabry Disease Market Company Profiles
  • 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. JCR Pharmaceuticals Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sumitomo Pharma Co. Ltd Overview, Products and Services, Strategy and Financial Analysis

31. Fabry Disease Market Other Major And Innovative Companies

• 31.1. Chiesi Farmaceutici S.p.A.
• 31.2. Amicus Therapeutics Inc.
• 31.3. Idorsia Pharmaceuticals Ltd
• 31.4. Sangamo Therapeutics Inc.
• 31.5. uniQure N.V.
• 31.6. Protalix BioTherapeutics Inc.
• 31.7. Spur Therapeutics Inc.
• 31.8. Exegenesis Bio Inc.
• 31.9. ISU ABXIS Co. Ltd.
• 31.10. Eleva GmbH
• 31.11. AceLink Therapeutics Inc.
• 31.12. 4D Molecular Therapeutics Inc.
• 31.13. iBio Inc.
• 31.14. Freeline Therapeutics Holdings plc
• 31.15. Greenovation Biotech GmbH

32. Global Fabry Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fabry Disease Market

34. Recent Developments In The Fabry Disease Market

35. Fabry Disease Market High Potential Countries, Segments and Strategies

• 35.1 Fabry Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Fabry Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Fabry Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료